Player FM 앱으로 오프라인으로 전환하세요!
Treating Hypersensitivity Disorders by Focusing on Specific Sodium Channel with John Mulcahy SiteOne Therapeutics TRANSCRIPT
Manage episode 292226149 series 99915
John Mulcahy PhD, President and CEO, SiteOne Therapeutics talks about broadening their pipeline from acute pain to hypersensitivity disorders like chronic cough and itching. Approach is to inhibit voltage-gated subtype sodium channel Nav1.7, a genetically validated target for pain. Stopping the pain signal in the peripheral nervous system before it gets to the spinal cord avoids some of the liabilities with existing pain medication like opioids. Lead candidate is now an intravenous analgesic showing proof of concept for the treatment of acute pain and itch.
#pain #hypersensitivity #sodiumchannels #opioids
1725 에피소드
Manage episode 292226149 series 99915
John Mulcahy PhD, President and CEO, SiteOne Therapeutics talks about broadening their pipeline from acute pain to hypersensitivity disorders like chronic cough and itching. Approach is to inhibit voltage-gated subtype sodium channel Nav1.7, a genetically validated target for pain. Stopping the pain signal in the peripheral nervous system before it gets to the spinal cord avoids some of the liabilities with existing pain medication like opioids. Lead candidate is now an intravenous analgesic showing proof of concept for the treatment of acute pain and itch.
#pain #hypersensitivity #sodiumchannels #opioids
1725 에피소드
모든 에피소드
×플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.